MSH6 is a protein that helps cells fix DNA mistakes. It is one of four mismatch repair proteins that pathologists test for in many cancers. When a tumor has lost MSH6, it cannot repair some of these mistakes. Loss of MSH6 can point to an inherited condition called Lynch syndrome. It can also affect which treatments your doctors consider. MSH6 results need careful interpretation, because weak or patchy staining can have other causes.
This article explains what MSH6 does, how pathologists test for it, what retained, lost, and patchy MSH6 results mean, and what happens next.
MSH6 works like a spell-checker for DNA. Cells make small copying mistakes each time they divide. MSH6 helps find these mistakes so other proteins can fix them.
MSH6 works with another protein, MSH2. The pair spots the mistake. A second pair, MLH1 and PMS2, then helps repair it. These four proteins make up the mismatch repair system.
The MSH6 gene holds the instructions for making the MSH6 protein. It is a tumor suppressor gene. When both copies stop working, mistakes build up in the DNA and can lead to cancer.
Pathologists test for MSH6 using immunohistochemistry. This test uses an antibody that sticks to the MSH6 protein in a thin slice of tumor tissue. Cells that contain MSH6 show brown staining in their nuclei.
Laboratories almost always test MSH6 together with MLH1, PMS2, and MSH2. Together, the four stains make up the mismatch repair, or MMR, panel. Laboratories commonly run this panel on colorectal and endometrial cancers, as well as many others.
The pathologist compares the tumor cells with normal cells on the same slide. Immune cells and other normal cells should always stain. They act as a built-in check that the test worked.
Your report will usually describe MSH6 as retained or lost. Some reports also describe a patchy or reduced pattern:
When a tumor keeps all four MMR proteins, pathologists call it mismatch repair proficient (pMMR).
The meaning of MSH6 loss depends on which other MMR proteins are also missing. Pathologists look at the four results together:
MSH6 staining can look patchy or weak for reasons other than an inherited change. Common causes include:
When MSH6 looks patchy after treatment, the pathologist may repeat the stain on the original biopsy taken before treatment. MSI testing can also help.
Loss of MSH6 leads to two separate questions for your care team. One is about your family, and one is about treatment.
The FDA has also approved other immunotherapy drugs for specific dMMR cancers. One example is dostarlimab, which received FDA approval in 2023 for advanced dMMR endometrial cancer that has grown after platinum chemotherapy. Approvals differ between countries. Your oncologist can explain which options apply to your cancer and stage.
🔍 Search MyPathologyReport
Type what you see on your report — for example a diagnosis or test name